HeXun Biosciences Co., Ltd. (TPEX:6986)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
51.10
-0.90 (-1.73%)
Mar 10, 2026, 1:58 PM CST
-33.20%
Market Cap 2.39B
Revenue (ttm) 290.83M
Net Income (ttm) 112.31M
Shares Out 46.00M
EPS (ttm) 2.44
PE Ratio 21.31
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 67,303
Average Volume 52,241
Open 52.10
Previous Close 52.00
Day's Range 50.70 - 52.50
52-Week Range 50.00 - 91.30
Beta -0.21
RSI 27.38
Earnings Date Mar 31, 2026

About HeXun Biosciences

HeXun Biosciences Co., Ltd. engages in the research and development of stem cell drug development and cardiovascular disease treatments in Taiwan. It provides contract manufacturing; commissioned inspection; aseptic filling; and consulting services. The company was founded in 2019 and is based in Taoyuan City, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 45
Stock Exchange Taipei Exchange
Ticker Symbol 6986
Full Company Profile

Financial Performance

In 2024, HeXun Biosciences's revenue was 286.42 million, an increase of 119.36% compared to the previous year's 130.57 million. Earnings were 147.22 million, an increase of 339.62%.

Financial Statements

News

There is no news available yet.